Iqra Mumal, MSc,  —

Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.

Articles by Iqra Mumal

Exercise May Benefit Cardiovascular, Mitochondrial Function in Huntington’s Patients, Study Suggests

Exercise training may help improve cardiovascular and mitochondrial function in patients with Huntington’s disease, with little to no treatment-related adverse events, a review study suggests. The study, “Exercise in Huntington’s Disease: Current State and Clinical Significance,” was published in the journal Tremor and Other Hyperkinetic Movements. Huntington’s…

Early Therapeutic Intervention Seen to Reverse Huntington’s Symptoms in Mouse Study

Huntington’s disease begins early, before birth, but symptoms tend to appear much later in life. Now, researchers working with mice have found a way to reverse so-called “pre-Huntington’s symptoms,” including abnormal nerve cell differentiation, with early therapeutic intervention. This could have important implications for future treatment strategies. The study, “Early postnatal…

Skyhawk, Celgene Partner to Develop Small Molecule Treatments for Huntington’s, Other Neurological Diseases

Skyhawk Therapeutics and Celgene have entered into a five-year global partnership to use Skyhawk’s STAR* technology platform to discover, advance, and commercialize new small-molecule therapies to treat patients with neurological diseases, including Huntington’s disease. The STAR* approach, which stands for “small-molecule therapies for alternative splicing in RNA,” aims to correct the…